Plastic Surgery Highlights: BRCA Breast Reconstruction

Economic Analysis Supports Access to Preventive Breast Cancer Care

A recent study in Plastic and Reconstructive Surgery confirms that prophylactic mastectomy with autologous reconstruction is cost-effective for women with BRCA1/2 mutations. These women face up to a 72% lifetime risk of breast cancer, making proactive treatment both life-saving and medically indicated.

In today’s cost-conscious healthcare system, being medically recommended isn’t always enough to ensure patient access. This research provides a clear financial rationale for insurance coverage. All autologous reconstruction options studied were cost-effective, with DIEP and TRAM flaps leading the way, giving insurers the data to confidently support coverage.

Studies like this are crucial. They protect and expand patient access to preventive care and reconstruction, allowing women to make informed, proactive health decisions without financial barriers.

Ultimately, this research empowers patients and providers alike, ensuring that high-quality preventive care and reconstruction remain accessible, not optional, in modern healthcare.

About This Research

Study Title: "Cost-Effectiveness of Prophylactic Mastectomy and Autologous Flap Reconstruction in BRCA1/2-Positive Patients"

Published in: Plastic and Reconstructive Surgery, October 2025

Research Team: Smith et al. from Stanford and Hofstra

‍